PMID- 34345170
OWN - NLM
STAT- MEDLINE
DCOM- 20210811
LR  - 20210811
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 16
DP  - 2021
TI  - Clinical Evolution and Quality of Life in Clinically Based COPD Chronic 
      Bronchitic and Emphysematous Phenotypes: Results from the 1-Year Follow-Up of the 
      STORICO Italian Observational Study.
PG  - 2133-2148
LID - 10.2147/COPD.S310428 [doi]
AB  - INTRODUCTION: Understanding clinical evolution of chronic obstructive pulmonary 
      disease (COPD) is crucial for improving disease management. MATERIALS AND 
      METHODS: STORICO (NCT03105999), an Italian, multicenter, non-interventional, 
      observational study conducted in 40 pulmonology centers, aimed to describe the 
      1-year clinical evolution and health status of clinicallbased phenotypes. 
      Baseline and follow-up data of COPD subjects with a chronic bronchitis (CB) or 
      emphysema (EM) phenotype were collected. The frequency of COPD symptoms during 
      the 24 hours (gathered via the night-time, morning and day-time symptoms of COPD 
      questionnaire) and the anxiety and depression levels (via the HADS Scale) were 
      recorded at each visit. RESULTS: A total of 261 CB and 159 EM patients were 
      analyzed. CB patients with >/=1 night-time symptom seemed to be more frequent 
      (51.7%, 41.8% and 41.4% at baseline, 6-month and 12-month follow-up, 
      respectively) than EM (37.7%, 32.1% and 30.2% at study visits) even if no 
      statistical differences were observed at time points between phenotypes 
      (chi-square test p-values presence/absence of night-time symptoms in CB vs EM at 
      study visits >0.0007). In the first 6 months, the frequency of patients with >/=1 
      night-time symptom decreased of 9.9% in CB and of 5.6% in EM. A clinically 
      relevant decline of DLCO % predicted over 1 year in EM was observed, the mean 
      (SD) being 61.5 (20.8) % at baseline and 59.1 (17.4) % at 12-month follow-up. EM 
      had higher levels of anxiety and depression than CB (median (25th-75th 
      percentile) HADS total score in CB: 7.0 (4.0-13.0) and 7.0 (3.0-12.0), in EM: 9.0 
      (3.0-14.0) and 9.5 (3.0-14.0) both at baseline and at 6-month follow-up, 
      respectively), considering 1.17 as minimally clinical important difference (MCID) 
      for the total score. CONCLUSION: EM patients, evaluated in a real-world setting, 
      seem to suffer from a worse clinical condition and health status compared to CB 
      patients, appearing to have "more treatable" traits.
CI  - (c) 2021 Blasi et al.
FAU - Blasi, Francesco
AU  - Blasi F
AD  - Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, 
      Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milan, Milan, 
      20122, Italy.
FAU - Antonelli Incalzi, Raffaele
AU  - Antonelli Incalzi R
AUID- ORCID: 0000-0003-2100-2075
AD  - University Biomedical Campus of Rome, Rome, 00128, Italy.
FAU - Canonica, Giorgio Walter
AU  - Canonica GW
AD  - Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, 
      Milan, Italy; IRCCS Humanitas Research Hospital, Personalized Medicine, Asthma 
      and Allergy, 20089, Rozzano, Milan, Italy.
FAU - Schino, Pietro
AU  - Schino P
AD  - Miulli Hospital, Acquaviva delle Fonti, Bari, 70021, Italy.
FAU - Cuttitta, Giuseppina
AU  - Cuttitta G
AD  - National Research Council, Palermo, 90146, Italy.
FAU - Zullo, Alessandro
AU  - Zullo A
AD  - Medineos Observational Research, Modena, 41123, Italy.
FAU - Ori, Alessandra
AU  - Ori A
AD  - Medineos Observational Research, Modena, 41123, Italy.
FAU - Scichilone, Nicola
AU  - Scichilone N
AUID- ORCID: 0000-0001-6400-6573
AD  - DIBIMIS, University of Palermo, Palermo, 90127, Italy.
CN  - STORICO study group
LA  - eng
SI  - ClinicalTrials.gov/NCT03105999
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20210721
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
SB  - IM
MH  - *Bronchitis, Chronic/diagnosis/epidemiology
MH  - *Emphysema
MH  - Follow-Up Studies
MH  - Humans
MH  - Italy/epidemiology
MH  - Phenotype
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis
MH  - Quality of Life
PMC - PMC8325060
OTO - NOTNLM
OT  - COPD
OT  - clinical evolution
OT  - clinical phenotype
OT  - quality of life
COIS- F.B. reports grants and personal fees from ASTRAZENECA, grants and personal fees 
      from BAYER, personal fees from CHIESI, personal fees from GSK, personal fees from 
      GUIDOTTI, grants and personal fees from GRIFOLS, grants from INSMED, personal 
      fees from MENARINI, personal fees from NOVARTIS, grants and personal fees from 
      PFIZER, personal fees from TEVA, personal fees from VERTEX, personal fees from 
      ZAMBON, outside the submitted work. G.C. reports personal fees for 
      speaker/advisory board fees from AstraZeneca, Chiesi, Menarini, Guidotti-Malesci, 
      Erbazeta, during the conduct of the study; personal fees from AstraZeneca, 
      Chiesi, Menarini, Erbazeta, Guidotti-Malesci, and Lusofarmaco, outside the 
      submitted work. A.Z. and A.O. are employees of Medineos Observational Research. 
      A.Z. reports personal fees from Laboratori Guidotti, during the conduct of the 
      study; personal fees from Chiesi, Novartis, AstraZeneca, and Novonordisk, outside 
      the submitted work. The other authors declare that they have no competing 
      interests.
EDAT- 2021/08/05 06:00
MHDA- 2021/08/12 06:00
PMCR- 2021/07/21
CRDT- 2021/08/04 07:04
PHST- 2021/03/17 00:00 [received]
PHST- 2021/06/30 00:00 [accepted]
PHST- 2021/08/04 07:04 [entrez]
PHST- 2021/08/05 06:00 [pubmed]
PHST- 2021/08/12 06:00 [medline]
PHST- 2021/07/21 00:00 [pmc-release]
AID - 310428 [pii]
AID - 10.2147/COPD.S310428 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2021 Jul 21;16:2133-2148. doi: 
      10.2147/COPD.S310428. eCollection 2021.